230 related articles for article (PubMed ID: 19243632)
21. Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations.
Oktay AN; Ilbasmis-Tamer S; Uludag O; Celebi N
Pharm Res; 2021 Jun; 38(6):991-1009. PubMed ID: 34086139
[TBL] [Abstract][Full Text] [Related]
22. Modification of oral absorption of oxyresveratrol using lipid based nanoparticles.
Sangsen Y; Wiwattanawongsa K; Likhitwitayawuid K; Sritularak B; Wiwattanapatapee R
Colloids Surf B Biointerfaces; 2015 Jul; 131():182-90. PubMed ID: 25988282
[TBL] [Abstract][Full Text] [Related]
23. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
Song A; Zhang X; Li Y; Mao X; Han F
Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
[TBL] [Abstract][Full Text] [Related]
24. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications.
Gokce EH; Korkmaz E; Dellera E; Sandri G; Bonferoni MC; Ozer O
Int J Nanomedicine; 2012; 7():1841-50. PubMed ID: 22605933
[TBL] [Abstract][Full Text] [Related]
25. Transdermal delivery of flurbiprofen: permeation enhancement, design, pharmacokinetic, and pharmacodynamic studies in albino rats.
Charoo NA; Anwer A; Kohli K; Pillai KK; Rahman Z
Pharm Dev Technol; 2005; 10(3):343-51. PubMed ID: 16176014
[TBL] [Abstract][Full Text] [Related]
26. Pluronic lecithin organogel as a topical drug delivery system.
Pandey M; Belgamwar V; Gattani S; Surana S; Tekade A
Drug Deliv; 2010 Jan; 17(1):38-47. PubMed ID: 22747074
[TBL] [Abstract][Full Text] [Related]
27. Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections.
Dudhipala N; Ay AA
Chem Phys Lipids; 2020 Oct; 232():104953. PubMed ID: 32814084
[TBL] [Abstract][Full Text] [Related]
28. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema.
Gao S; Tian B; Han J; Zhang J; Shi Y; Lv Q; Li K
Int J Nanomedicine; 2019; 14():6135-6150. PubMed ID: 31447556
[No Abstract] [Full Text] [Related]
29. Solid lipid nanoparticles (SLNs) gels for topical delivery of aceclofenac in vitro and in vivo evaluation.
Dasgupta S; Ghosh SK; Ray S; Mazumder B
Curr Drug Deliv; 2013 Dec; 10(6):656-66. PubMed ID: 24274634
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Assessment of Steroidal Nanostructured Lipid Carriers Based Gels for Atopic Dermatitis: Optimization and Product Development.
Nagaich U; Gulati N
Curr Drug Deliv; 2018; 15(5):641-651. PubMed ID: 28925874
[TBL] [Abstract][Full Text] [Related]
31. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Fang JY; Fang CL; Liu CH; Su YH
Eur J Pharm Biopharm; 2008 Oct; 70(2):633-40. PubMed ID: 18577447
[TBL] [Abstract][Full Text] [Related]
32. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery.
Gonzalez-Mira E; Egea MA; Souto EB; Calpena AC; García ML
Nanotechnology; 2011 Jan; 22(4):045101. PubMed ID: 21169662
[TBL] [Abstract][Full Text] [Related]
33. Development of nitrendipine controlled release formulations based on SLN and NLC for topical delivery: in vitro and ex vivo characterization.
Bhaskar K; Krishna Mohan C; Lingam M; Prabhakar Reddy V; Venkateswarlu V; Madhusudan Rao Y
Drug Dev Ind Pharm; 2008 Jul; 34(7):719-25. PubMed ID: 18612912
[TBL] [Abstract][Full Text] [Related]
34. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC.
Gonzalez-Mira E; Egea MA; Garcia ML; Souto EB
Colloids Surf B Biointerfaces; 2010 Dec; 81(2):412-21. PubMed ID: 20719479
[TBL] [Abstract][Full Text] [Related]
35. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
36. Investigation of nanostructured lipid carriers for transdermal delivery of flurbiprofen.
Han F; Li S; Yin R; Shi X; Jia Q
Drug Dev Ind Pharm; 2008 Apr; 34(4):453-8. PubMed ID: 18401788
[TBL] [Abstract][Full Text] [Related]
37. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen.
González-Mira E; Nikolić S; García ML; Egea MA; Souto EB; Calpena AC
J Pharm Sci; 2011 Jan; 100(1):242-51. PubMed ID: 20575052
[TBL] [Abstract][Full Text] [Related]
38. Lipid nanoparticles as carrier for octyl-methoxycinnamate: in vitro percutaneous absorption and photostability studies.
Puglia C; Bonina F; Rizza L; Blasi P; Schoubben A; Perrotta R; Tarico MS; Damiani E
J Pharm Sci; 2012 Jan; 101(1):301-11. PubMed ID: 21905033
[TBL] [Abstract][Full Text] [Related]
39. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
40. Solid lipid nanoparticles for transdermal delivery of avanafil: optimization, formulation, in-vitro and ex-vivo studies.
Kurakula M; Ahmed OA; Fahmy UA; Ahmed TA
J Liposome Res; 2016 Dec; 26(4):288-96. PubMed ID: 26784833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]